Gene Therapy Advances in Marfan Syndrome Treatment

A new research report from the College of Medical Technology has outlined the progress made in treating Marfan syndrome, a hereditary connective tissue disorder caused by mutations in the fibrillin-1 (FBN1) gene. According to the study, gene therapy and emerging technologies such as CRISPR-Cas9 gene editing and induced pluripotent stem cell (iPSC) are being explored as novel platforms for drug discovery and personalized therapeutic exploration. The research highlights the current limitations of conventional treatments and the need for innovative approaches to manage life-threatening cardiovascular complications associated with the disease.

Key Takeaways:

• Marfan syndrome primarily affects the eyes, bones, and cardiovascular system, with cardiovascular complications posing the most significant threat to life.
• Conventional treatments for Marfan syndrome are based on pharmacological management and surgical interventions, which aim to slow disease progression and manage life-threatening cardiovascular complications.
• Emerging technologies such as CRISPR-Cas9 gene editing and induced pluripotent stem cell (iPSC) have advanced the understanding of FBN1 mutation heterogeneity and disease mechanisms beyond TGF-b signaling.
• Gene therapy and novel therapeutic approaches are being explored as potential future applications in Marfan syndrome treatment.
• The study highlights the importance of personalized therapy and personalized medicine in addressing the complex needs of patients with Marfan syndrome.
• The research focuses on surgical innovations, emerging medicine, and therapeutic targets, while discussing the potential future applications of gene therapy.
• The study emphasizes the need for further research and development of innovative treatments for Marfan syndrome.

Statistics:

• Marfan syndrome affects approximately 1 in 5,000 to 1 in 10,000 people worldwide (Source: College of Medical Technology).
• Cardiovascular complications are the leading cause of death in individuals with Marfan syndrome, accounting for up to 90% of fatalities (Source: College of Medical Technology).

Sources:

• Feng X, et al. (2025). Therapeutic Opportunities of Marfan Syndrome: Current Perspectives. Drug Design, Development and Therapy, Volume 19(Issue 1):7365-7379. (http://www.dovepress.com/drug-design-development-and-therapy-journal)
• NewsRx. Research on Gene Therapy Published by Researchers at College of Medical Technology (Therapeutic Opportunities of Marfan Syndrome: Current Perspectives). Cardiovascular Week. September 8, 2025; p 126.